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A B S T R A C T
Synthetic glucocorticoids are widely prescribed for the treatment of numerous inflammatory and autoimmune
diseases and they can also affect the way the adrenal gland produces endogenous glucocorticoids. Indeed, pa-
tients undergoing synthetic glucocorticoid treatment can develop adrenal insufficiency, a condition char-
acterised by reduced responsiveness of the adrenal to ACTH stimulation or stressors (e.g. surgical or in-
flammatory stress). To better elucidate the long-term effect of synthetic glucocorticoids treatment and
withdrawal on adrenal function, we have investigated the long-term effects of prolonged treatment with me-
thylprednisolone on HPA axis dynamics and on the adrenal steroidogenic pathway, both in basal conditions and
in response to an inflammatory stress (lipopolysaccharide, LPS).
We have found that 5-days treatment with methylprednisolone suppresses basal ACTH and corticosterone
secretion, as well as corticosterone secretion in response to a high dose of ACTH, and down-regulates key genes
in the adrenal steroidogenic pathway, including StAR, MRAP, CYP11a1 and CYP11b1. These effects were par-
alleled by changes in the adrenal expression of transcription factors regulating steroidogenic gene expression, as
well as changes in the expression of adrenal clock genes. Importantly, 5 days after withdrawal of the treatment,
ACTH levels are restored, yet basal levels of corticosterone, as well as most of the key steroidogenic genes and
their regulators, remain down regulated. We also show that, although 5-days treatment with methylprednisolone
reduces the corticosterone response to LPS, an increase in intra-adrenal pro-inflammatory cytokine gene ex-
pression was observed.
Our data suggests that the steroidogenic pathway is directly affected by synthetic glucocorticoid treatment in
the long-term, presumably via a mechanism involving activation of the glucocorticoid receptor. Furthermore,
our data suggests a pro-inflammatory effect of synthetic glucocorticoids treatment in the adrenal gland.
1. Introduction
Glucocorticoids hormones (GCs) are the final product resulting from
activation of the hypothalamic pituitary adrenal (HPA) axis in response
to circadian cues and to stress. They are synthesized by the adrenal
gland in response to stimulation by adrenocorticotropic hormone
(ACTH), which is secreted by the anterior pituitary in response to
corticotrophin-releasing hormone and arginine vasopressin released
from hypothalamic paraventricular neurons. Glucocorticoids regulate
many physiological functions, including metabolism, cardiovascular
tone, reproduction, mood and cognition, and the immune system. In
addition, GCs regulate their own production through negative feedback
on ACTH and CRH secretion (Spiga et al., 2014).
Because of their effect on the immune system, synthetic GC (SGC)
therapy is widely prescribed for the treatment of inflammatory and
autoimmune diseases. However, the therapeutic actions of SGCs are
accompanied by several adverse side effects, which are more frequent
following high doses and long-term treatments. Importantly, patients
undergoing SGC treatment can also develop adrenal insufficiency fol-
lowing prolonged treatment, due to chronic glucocorticoid-induced
inhibition of the HPA axis. This condition is characterised by reduced
responsiveness of the adrenal gland to ACTH stimulation, and adrenal
crisis/shock can occur in response to acute physiological stress (e.g.
surgical or inflammatory stress). Importantly, there is a correlation
between duration of SGC treatment and the reduction in adrenal re-
sponsiveness, as well as its recovery to normal function. Indeed, some
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studies have shown that it can take more than a year for a suppressed
adrenal to recover after long-term SGC treatment, whereas very rapid
recovery within a day or so has been observed in patients that have only
been treated for 1–2 weeks (Paragliola et al., 2017).
Previous studies have concentrated on long-term inhibitory effects
of SGC treatment at the level of the hypothalamus and pituitary but
have tended to ignore the powerful direct effects that these steroids
may have at the level of the adrenal itself. Since ACTH is necessary for
maintenance of steroidogenic activity, it is often assumed that SCG
mediated adrenal insufficiency is solely due to suppression of ACTH.
However, our previous data in the rat shows that the SGC methyl-
prednisolone (MPRED) not only suppresses ACTH and corticosterone
secretion, but also down-regulates key genes within the adrenal ster-
oidogenic pathway. The same study also showed that pulsatile admin-
istration of ACTH could prevent the effects of SGC treatment on both
corticosterone secretion and steroidogenic gene expression (Spiga et al.,
2011). Furthermore a direct effect of glucocorticoids on the expression
of some key steroidogenic genes has already been described (Peron
et al., 1960; Carsia and Malamed, 1979; Loose et al., 1980; Gummow
et al., 2006). More recently, using in vivo experiments in the rat and
mathematical modelling, we were able to show that activation of the
glucocorticoid receptor (GR) in the adrenal gland can indeed down
regulate the steroidogenic response to ACTH (Walker et al., 2015; Spiga
et al., 2017) and a more recent study has reported the presence of a
negative glucocorticoid responsive element within the promoter of
steroidogenic genes (Wang et al., 2019). Therefore, we hypothesised
that glucocorticoid-induced long-term changes in the adrenal gland
steroidogenic pathways may also be responsible for adrenal suppres-
sion.
We have previously shown that 5-days continuous treatment with
MPRED in the drinking water suppresses basal secretion of the en-
dogenous GC corticosterone in the rat, and this effect was associated
with decreased expression of key steroidogenic gene including StAR,
CYP11a1 and MRAP (Spiga et al., 2011). Although this study clearly
showed a link between decreased corticosterone secretion and changes
in steroidogenic gene expression, a limitation of our previous work was
the small numbers of steroidogenic genes measured, as well as the lack
of investigation on other factors known to regulate steroidogenic
pathways. Indeed, we have recently shown that GC production in the
adrenal gland is governed by complex dynamic interactions between
components of the steroidogenic regulatory network (Spiga et al.,
2017). Therefore, in the present study we made our investigation more
comprehensive by including the expression of a larger number of genes
within the adrenal steroidogenic pathway, and other genes that are
known to be involved in the regulation of glucocorticoid synthesis,
including transcription factors and nuclear receptors, as well as clock
genes and inflammatory modulators. This approach allowed us to ex-
pand on our previous work and to show that long-term treatment with
SGCs can indeed down-regulate adrenal steroidogenic activity both
directly by regulating the expression of specific steroidogenic genes,
and indirectly, by affecting other signalling pathways. Furthermore, we
have investigated the long-term effects of prolonged MPRED treatment
on the hormonal and adrenal response to endotoxin, and we have found
that there is an increase in the intra-adrenal cytokines IL-1β and TNFα
in parallel to the decreased corticosterone response to inflammation.
Thus, our data provide evidence of a pro-inflammatory effect of SGCs in
the adrenal gland that, in the long-term, may contribute to further
aggravation of the already-disrupted adrenal steroidogenic activity.
2. Material and methods
2.1. Animals
All experiments were conducted on adult male Sprague–Dawley rats
(Harlan Laboratories, Inc., Blackthorn, UK) weighting 200–220 g at the
time of arrival. Animals were given a 1-week acclimatization period
prior to the start of the experiments, they were maintained under a 14 h
light, 10 h dark schedule (lights on at 0500 h) and housed four per cage
with ad libitum access to food and water. All animal procedures were
approved by the University of Bristol Ethical Review, comply with the
ARRIVE guidelines and were carried out in accordance with the U.K.
Animals (Scientific Procedures) Act, 1986.
2.2. Methylprednisolone treatment
Rats were assigned to each treatment group randomly. Rats were
either left untreated (control group, Ctrl), treated with methylpredni-
solone (MP; methylprednisolone sodium succinate, Solu-Medrone,
Upjohn Pharmaceuticals, UK) in the drinking water (1 g/L) for 5 days
(MP treatment group, MPT), or treated with MP for 5 days and then left
to recover for 5 days (MP recovery group, MPR). Because high doses of
synthetic glucocorticoids have been shown to decrease body weight in
the rat, the efficacy of the MP treatment, and withdraw from it, was
monitored through the treatment by assessing the rats body weight
(Suppl. Fig. 1).
2.3. Experiments
Experiment 1 was designed to determine the effect of MP treatment
and recovery on basal circadian and ultradian rhythms of corticos-
terone and the adrenal response to ACTH. On day 5 of treatment rats
were anesthetized using isoflurane, and an indwelling catheter was
inserted in the right jugular vein as previously described (Spiga et al.,
2011). On day 10 of treatment rats were connected to an automated
blood sampling system as previously described (Spiga et al., 2011),
blood samples were collected every 10 min from 07:00 of for 24 h at a
dilution of 1:5 in heparinized saline and each sample from the auto-
mated system contained no more than 40 μl of whole blood. On day 11
at 7:00 rats were injected with ACTH (16 ng/rat, i.v.; Synacthen, Alli-
ance Pharma, Cheltenham, United Kingdom) and samples were col-
lected every 10 min for 60 min after the injection. Corticosterone levels
were analysed using radioimmunoassay (RIA) as previously shown
(Spiga et al., 2011). Experiment 2 was designed to determine the effect
of MP treatment and recovery on gene and protein expression in the
hypothalamus, anterior pituitary and adrenal gland during the nadir (9
AM) and the peak (5 PM) of HPA axis activity. Experiment 3 was de-
signed to determine the effect of MP treatment and recovery on the
adrenal response to inflammatory stress. Rats were treated with MP and
then injected with lipopolysaccharide (LPS; Escherichia coli, clone
055:B5; 250 μg/kg in 0.1 mL of sterile saline; Sigma, Dorset, United
Kingdom).
2.4. Tissue collection
At the end of experiment 1, rats were overdosed with 0.2 mL of
sodium pentobarbitone (Euthatal, 200 mg/mL; Merial, Harlow, United
Kingdom). At the end of experiment 2 and 3 rats were anaesthetised
with isoflurane and killed by decapitation, trunk blood was collected in
ice-cold tubes containing EDTA (0.5 M; pH 7.4) and Trasylol
(Aprotinin, 500,000 KIU/mL, Roche Diagnostics). Plasma was sepa-
rated by centrifugation and then stored at –80 °C until processed for
ACTH and corticosterone measurement. Adrenal glands were collected
and the inner zones (comprising the zona fasciculata and the zona re-
ticularis of the cortex and the adrenal medulla) were separated from the
outer zone (containing the zona glomerulosa and the capsula). Individual
inner zones were immediately frozen until processing for isolation of
RNA for real-time quantitative PCR (left adrenal) and for protein ex-
traction for Western immunoblotting and corticosterone measurement
(right adrenal) as previously described (Spiga et al., 2017). In experi-
ment 2 pituitaries and brains were also collected, and from each rat
anterior pituitary and hypothalamus were dissected and immediately
frozen until processing for isolation of RNA for real-time quantitative
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PCR. In experiments 2 and 3, liver was also collected and immediately
frozen until processing for isolation of RNA for real-time quantitative
PCR.
2.5. RNA isolation and RT-qPCR
Total RNA was extracted from the inner zone each right adrenal,
and from the liver, anterior pituitary and the hypothalamus using
TRIzol reagent (Invitrogen, Hopkinton, MA, USA), followed by pur-
ification using RNeasy mini kit reagents, and column DNase digestion
(Qiagen, Valencia, CA, USA) to remove genomic DNA contamination.
Complementary DNA was reverse transcribed from 1 μg of total RNA
using Cloned AMV First-Strand cDNA synthesis kit (Invitrogen). Fast
SYBRGreen Master Mix (Applied Biosystems, Foster City, CA, USA) was
used for the amplification mixture with each primer at a final con-
centration of 200 nm and 2 μl of cDNA for a total reaction volume of
25 μl. All primers were purchased from Invitrogen and were designed to
span exon/exon boundaries (Suppl. Table S1). PCR reactions were
performed on a spectrofluorometric thermal cycler. The expression of
each target gene was normalized to actin mRNA as determined in a
separate real-time PCR reaction. The absence of RNA detection when
the reverse transcription step was omitted indicated the lack of genomic
DNA contamination in the RNA samples.
2.6. Western immunoblotting
Whole cell lysate from the inner zone of individual left adrenals
were prepared using RIPA buffer (Sigma) supplemented with 0.2 mM
Na orthovanadate, 2 mM NaF, and Complete Protease Inhibitor (Roche
Diagnostics Ltd., Burgess Hill, UK). Protein concentration was quanti-
fied by spectrophotometry using the Pierce BCA protein assays,
(Thermo Fisher Scientific Inc. Rockford, IL, USA). Aliquots of each
sample (10–15 μg of protein) were loaded and separated in a 10% or
4–15% Tris–Glycine gel (BioRad, Hercules, CA, USA), transferred to a
PVD membrane (GE Amersham Biosciences, Piscataway, NJ, USA),
blocked with 5% non-fat milk or 1% bovine serum albumin (BSA,
sigma) in 1 × Tris-buffered saline plus 0.05% Tween 20 (TBST) and
incubated overnight with Aliquots of each sample (10–15 μg of protein)
were loaded and separated in a 10% or 4–15% Tris–Glycine gel
(BioRad, Hercules, CA, USA), transferred to a PVD membrane (GE
Amersham Biosciences, Piscataway, NJ, USA), blocked with 5% non-fat
milk or 1% bovine serum albumin (BSA, sigma) in 1 × Tris-buffered
saline plus 0.05% Tween 20 (TBST) and incubated overnight with an-
tibodies to StAR and HSL (at 1:1000 dilution, Santa Cruz
Biotechnologies, Inc., Dallas, TX, US). After washing with TBST, the
membranes were incubated with a horseradish peroxidase-conjugated
donkey anti-rabbit IgG (at 1:10000 dilution; Santa Cruz
Biotechnologies). After StAR an HSL bands exposure, blots were
stripped and assayed for GAPDH (at 1:5000 dilution; Cell Signalling
Technology, Inc., USA). Protein bands were visualised with Luminata
Forte Western HRP substrate (Millipore Corporation, Billerica, MA,
USA) using a G BOX (Syngene, Cambridge, UK) and densitometry was
determined using Image J (developed at the National Institutes of
Health and freely available at: http://rsb.info.nih.gov). Data points for
each gene were then normalized relative to the GAPDH band in the
respective sample.
2.7. Hormone measurement
Adrenal CORT was measured in adrenal whole cell extract prepared
for Western blotting and CORT levels were normalized to the total
protein content. Corticosterone concentration was measured in diluted
whole blood or plasma in samples obtained with the automatic blood
sampling system or from the trunk blood, respectively. Total blood,
plasma and adrenal CORT was measured by radioimmunoassay (RIA)
using a citrate buffer (pH 3.0) to denature the binding globulin as
previously described (Spiga et al., 2017). Antiserum was kindly sup-
plied by Professor Gabor Makara (Institute of Experimental Medicine,
Budapest, Hungary) and [125I] CORT was purchased from Izotop
(Budapest, Hungary). ACTH concentration in plasma samples was
measured by RIA using a commercially available assay (MP Biomedi-
cals, Santa Ana, California, USA) in accordance with the manufacturer’s
instructions.
2.8. Statistics
Sample sizes in each experiment were determined on the basis of
pilot studies and previous experience with similar experimental design.
Animals were allocated to each experimental group (treatment and time
of kill) by simple randomization. Experimenters were blinded to the
experimental group at the time of hormones, mRNA and protein mea-
surements. Graph Pad Prism version 7.00 (Graph Pad Software, La
Jolla, CA, USA) and SPSS version 24 (IBM Corp., Armonk, NY, USA)
were used for data graphing and statistical analysis, respectively. Data
are represented as the mean ± SEM, mRNA and protein data are ex-
pressed as fold induction of Ctrl AM. Parameters characterizing the
pulses of corticosterone were analysed in individual profile using
PULSAR algorithm (Merriam and Wachter, 1982) as previously de-
scribed (Spiga et al., 2011). The overall effect of treatments was ana-
lysed using unpaired t-test, or One-Way or Two-Way ANOVA followed
by Tuckey post-hoc test, as indicated in each figure legend. Details of
statistical significances for each experiment are reported in Suppl.
Tables 2 and 3. Statistical significance was set at P ≤ 0.05.
3. Results
3.1. Prolonged treatment with MPRED decreases basal corticosterone
secretion and the adrenal response to ACTH
Under basal, unstressed, conditions corticosterone secretion in the
rat exhibits ultradian oscillations, characterised by hourly pulses of
hormone secretion, and the amplitude of these pulses varies in a cir-
cadian manner with larger pulses occurring at the start of the active
phase (early-evening in the rat) (Windle et al., 1998; Spiga et al., 2014).
We used an automated blood sampling system to assess the effects of
MPRED treatment on basal corticosterone circadian and ultradian
rhythms, as well as on corticosterone pulse dynamics (Fig. 1A). Analysis
of corticosterone secretion in Ctrl rats showed the well-characterised
ultradian and circadian patterns (Fig. 1B and Suppl. Fig. 2A), with
corticosterone secretion parameters and pulse characteristics, analysed
across the 24-h hormone profile using the PULSAR algorithm, that were
as previously reported (Seale et al., 2004; Spiga et al., 2011) (Suppl.
Table 2). In contrast, and as reported in previous studies (Spiga et al.,
2011), 5-days treatment with MPRED suppressed basal corticosterone
secretion, as shown by almost undetectable levels of hormone through
the 24-h period (MP-T rats; Fig. 1B and Suppl. Fig. 2B). Importantly,
5 days after withdrawing from the treatment basal corticosterone levels
appeared to be still significantly lower than the Ctrl group (MP-W
group; Fig. 1B and Suppl. Fig. 2C), as shown by a decreased mean, max
and 24-h AUC corticosterone levels (Suppl. Table 2). Analysis of cor-
ticosterone pulse characteristics with the PULSAR algorithm revealed a
decrease in the pulse amplitude and length, as well as a decrease in
pulse frequency, and an increase in the inter-pulse interval time and in
the pulse length in MP-W rats, compared to Ctrl (Suppl. Table 2). In
addition to a decrease in basal corticosterone secretion, we also ob-
served an effect of MPRED treatment on the adrenal response to ACTH
(treatment: F(2,97) = 25.32; P < 0.0001; Fig. 1C), with corticosterone
secretion significantly reduced in both MP-T and MP-W group.
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Interestingly, while basal corticosterone secretion was partially re-
covered in MP-W rats (Fig. 1B, Suppl. Table 2), adrenal response to
ACTH in this group was not different from MP-T group, suggesting that
long-term changes in the adrenal gland may occur after MPRED treat-
ment, and persist even after discontinuation of the treatment.
To investigate whether the changes in basal and ACTH-induced
corticosterone secretion in MP-T and MP-W rats were due to the effects
of MPRED on hypothalamic-pituitary activity, as well as a direct effect
on adrenal steroidogenic function, we repeated the MPRED treatment
in a different cohort of rats and we collected trunk blood samples,
hypothalamus, pituitary and adrenals both in the morning (09:00, AM)
and in the evening (19:00, PM), that is at the nadir and at the peak time
of corticosterone secretion. Analysis of HPA axis-related genes in the
whole hypothalamus and anterior pituitary revealed that hypothalamic
CRH mRNA and AVP mRNA, and pituitary POMC mRNA and CRHR1
mRNA levels were unaffected by MPRED treatment (Suppl. Fig. 3A and
B). In addition, while the expression of pituitary glucocorticoid and
mineralocorticoid receptors (GR and MR, respectively), which mediate
the effects of GC-negative feedback, was also unaffected by MPRED
treatment (Suppl. Fig. 3C), an increase in GR mRNA in the hypotha-
lamus was found in MP-W rats (treatment: F(2, 34) = 4.25; P = 0.024;
Suppl. Fig. 3D).
Interestingly, although we found no changes in pituitary POMC
mRNA, the effects of MPRED on corticosterone secretion were asso-
ciated with reduced basal ACTH secretion in the PM (time × treatment:
F(2, 32) = 7.042; P = 0.003) as well as with reduced adrenal corti-
costerone levels (time × treatment: F(2, 32) = 17.43; P < 0.00001) and
adrenal weight (treatment: F(2, 32) = 18.45; P < 0.00001) in the PM
and in the AM, respectively (Fig. 2B). However, while ACTH levels
returned to normal after 5 days recovery from MPRED treatment, both
adrenal corticosterone levels and adrenal weight were reduced in MP-W
rats. Detailed results of statistical analysis are reported in Suppl.
Table 3.
3.2. Reduced corticosterone secretion in rats treated with MPRED is
associated with decreased expression of adrenal steroidogenic proteins
The observation that corticosterone levels are reduced both during
the MPRED treatment and after 5 days withdraw lead us to investigate
the effect of MPRED treatment on the adrenal steroidogenic pathway
(Fig. 2C and D). We found that MPRED treatment affected the relative
expression of MRAP mRNA (time × treatment: F(2, 32) = 16.05;
P < 0.00001), HSL mRNA (time × treatment: F(2, 32) = 4.79;
P = 0.0173), StAR mRNA (time × treatment: F(2, 32) = 15.68;
P=<0.00001), TSPO mRNA (treatment: F(2, 32) = 23.1;
P < 0.00001), Cyp11a1 mRNA (time × treatment: F(2, 32) = 10.46;
P < 0.00001), HSD3b1 mRNA (time × treatment: F(2, 32) = 4.02;
P = 0.03), Cyp21a1 mRNA (treatment: F(2, 32) = 32.04; P < 0.00001)
and Cyp11b1 mRNA (treatment: F(2, 32) = 39.87; P < 0.00001), with a
reduction in both MP-T and MP-W rats (Fig. 2C). Interestingly, an in-
crease in HSD11b1 mRNA in the in MP-T rats was also observed
(time × treatment: F(2, 32) = 4.91; P = 0.015), suggesting that re-
activation of corticosterone from its metabolite 11-dehy-
drocorticosterone may be a compensatory mechanism to overcome the
lack of steroidogenic activity, due to reduced ACTH and subsequent
decreased steroidogenic genes expression. This effect was found to be
specific to the adrenal gland, as HSD11b1 expression in the liver of MP-
T rats was unaffected (Suppl. Fig. 4). In addition, a reduction in the
expression of the gene encoding for PDE8b the main phosphodiesterase
expressed in the adrenal regulating the levels of cAMP (Tsai et al.,
2011), was also observed in MP-T and MP-W rats (time × treatment: F(2,
32) = 24.44; P < 0.00001). These findings suggest that reduced basal
and ACTH-induced adrenal activity, and thus corticosterone secretion,
in MP-W rats is due to decreased activity of the whole steroidogenic
pathway. The effects of MPRED on steroidogenic gene expression in
MP-T and MP-W rats also lead to significant changes in their AM/PM
expression pattern. Specifically, MPRED treatment resulted in a loss of
Fig. 1. Effect of MPRED treatment and recovery on basal and ACTH induced corticosterone secretion. (A) Schematic representation of the basal ultradian rhythm and
ACTH injection experiments using automated blood sampling experiment. (B) Mean ± SEM corticosterone profiles from untreated rats (control group, Ctrl; n = 7),
rats treated with methylprednisolone (MPRED) in the drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T; n = 6), and rats treated with MPRED for
5 days and then left to recover for 5 days (MPRED withdraw group, MP-W; n = 7). Individual profiles from rats in each experimental group are reported in Suppl.
Fig. 1. Blood samples were collected every 10 min from 07:00 on day 1 for 24 h using an automated blood sampling system. Corticosterone secretion parameters and
pulse dynamics characteristics from each individual profile were analysed using the PULSAR algorithm and data are shown in Suppl. Table 2A and B. Gray bar
represents the dark period (19:00–05:00). (C) Time course of plasma corticosterone response to ACTH administration (16 ng, i.v.). Data were analysed by repeated
measures ANOVA and Tukey post-hoc test. *P < 0.05 vs time 0 (effect of ACTH); ^P < 0.05 vs Ctrl at the same time.
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Fig. 2. Effect of MPRED treatment and recovery on HPA axis and adrenal steroidogenic pathway. (A) Schematic representation of the AM and PM experiments.
Plasma ACTH, adrenal corticosterone levels and relative adrenal weight (normalised to 100 g of body weight) (B), relative expression of steroidogenic genes mRNA
(C) and steroidogenic proteins (D) were measured at 09:00 (AM) and at 19:00 (PM) in untreated rats (control group, Ctrl), rats treated with methylprednisolone
(MPRED) in the drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T), and rats treated with MPRED for 5 days and then left to recover for 5 days
(MPRED withdraw group, MP-W). All data are mean ± SEM of 5–8 rats/group and are expressed as fold induction of AM-Ctrl. Data were analysed by two-way
ANOVA and Tukey post-hoc test. *P < 0.05 vs Ctrl at the same time of day (effect of treatment); ^P < 0.05 vs MPT at the same time of day (effect of treatment);
§P < 0.05 vs AM of the same treatment group (effect of time of day). Symbols in parentheses indicate a tendency to significance (P < 0.10).
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AM/PM variation in MRAP, HSL, StAR and HSD3b1 mRNA. The effects
of MPRED on HSL and StAR mRNA were also found in the expression of
their respective proteins (Fig. 2D), with HSL and StAR proteins de-
creased in MP-T rats, and not fully recovered in MP-W rats (HSL
treatment: F(2, 32) = 9.51; P = 0.001; StAR treatment: F(2, 32) = 13.77;
P < 0.00001; StAR time: F(1, 32) = 7.36; P = 0.011). Detailed results of
statistical analysis are reported in Suppl. Table 3.
3.3. MPRED affects the expression of genes encoding for adrenal
transcription factors and regulators of steroidogenic gene expression and
function
The transcription of adrenal steroidogenic genes is regulated by a
number of transcription factors, nuclear receptors and regulators, and
the activity and expression of most of these are also under the control of
ACTH. Specifically, ACTH-induced phosphorylation of CREB require
the activation of several nuclear receptors and co-regulators, including
members of the CRTC family (CRTC1-3) (Smith et al., 2019), Nur77
(Martin et al., 2008) and steroidogenic factor 1 (SF-1) (Sugawara et al.,
1996), and the repression of a number of negative regulators, including
salt inducible kinase 1 (SIK1) (Takemori and Okamoto, 2008) and do-
sage sensitive sex-reversal, adrenal hypoplasia (Zazopoulos et al.,
1997). Interestingly, GCs can inhibit the transcription of steroidogenic
genes through a mechanism that involves increase in the expression of
the steroidogenic co-repressor dosage-sensitive sex reversal, adrenal
hypoplasia critical region, on chromosome X, gene 1 (DAX-1)
(Gummow et al., 2006) as well as by inhibiting both the transcription
and the activity of Nur77 via a mechanism that involves active GR
(Song et al., 2004; Martin and Tremblay, 2008).
Therefore, to investigate the mechanism underlying the changes in
steroidogenic genes and proteins induced by MPRED, we measured the
expression of genes encoding for transcription factors that are known to
be involved in the regulation of steroidogenic genes expression as de-
scribed above. Consistent with the effects of MPRED treatment on
steroidogenic genes expression, we found changes in Nur77 mRNA
(time × treatment: F(2, 32) = 10.35; P < 0.00001), SF-1 mRNA
(time × treatment: F(2, 32) = 4.89; P = 0.015), DAX-1 mRNA
(time × treatment: F(2, 32) = 6.28; P = 0.006), CRTC1 mRNA (treatment:
F(2, 32) = 4.03; P = 0.029), CRTC2 mRNA (time × treatment: F(2,
32) = 3.68; P = 0.039), CRTC3 mRNA (time × treatment: F(2,
32) = 24.44; P < 0.00001) and SIK1 mRNA (time × treatment: F(2,
32) = 5.11; P = 0.013) (Fig. 3). To our surprise, none of the genes
encoding for steroidogenic transcription factors or transcriptional co-
regulators were either up- or down-regulated after withdrawing the
MPRED treatment. As observed for steroidogenic genes expression, we
found significant changes in the AM/PM expression of genes encoding
for adrenal transcription factors. A loss in AM/PM difference was ob-
served in Nur77, SF-1 and SIK1 mRNA in MP-T rats, whereas a gain in
AM/PM difference was observed in CRTC3 mRNA in MP-W rats
(AM > PM). Detailed results of statistical analysis are reported in
Suppl. Table 3.
3.4. MPRED affects the expression of adrenal clock genes
As observed in the brain and in other peripheral organs, the adrenal
gland expresses clock genes, and, as shown in this study and consistent
with our previous report (Park et al., 2013), the expression of many
steroidogenic genes and their transcriptional regulators is characterised
by AM/PM differences. The crosstalk between glucocorticoids, clock
genes and steroidogenic genes is complex. In vivo studies have shown
that treatment with SGCs alters the pattern of circadian clock gene
expression in various peripheral tissues (Balsalobre et al., 2000; Sujino
et al., 2012). The molecular mechanisms underlying the effect of GCs on
clock gene expression have been addressed by several groups and there
is evidence that GCs regulate the expression of clock genes, including
enhanced expression of Period 1 (Per1) and reduced expression of REV-
ERBα (Torra et al., 2000), via the glucocorticoid receptor (GR) pathway
(Nader et al., 2010). In turn, GR activity can be regulated by clock
proteins, including CLOCK and Cryptochrome 1 and 2 (Cry1 and Cry2)
(Nader et al., 2009; Lamia et al., 2011) via non-genomic mechanisms.
With regard to a link between clock genes and adrenal steroidogenic
pathways, studies in mice have shown that the expression of StAR is
regulated by the activity of the CLOCK-BMAL complex (Son et al., 2008;
Leliavski et al., 2014) and mutation in the Bmal gene in the adrenal
gland leads to loss of corticosterone circadian rhythm in mice housed in
altered light cycle (Son et al., 2008; Engeland et al., 2018). In light of
this, we hypothesised that the changes in the expression of steroido-
genic genes observed in MP-T and in MP-W rats may be associated with
changes in adrenal clock genes expression. We found that MPRED
treatment affected the expression of all clock genes studied (Fig. 4).
Specifically, we found a decrease in the expression of BMAL mRNA
(time × treatment: F(2, 32) = 5.85; P < 0.008), CLOCK mRNA (treat-
ment: F(2, 32) = 4.10; P = 0.028), Per1 mRNA (time × treatment: F(2,
32) = 4.53; P = 0.02), Per2 mRNA (time × treatment: F(2, 32) = 12.87;
P < 0.00001), Cry1 mRNA (time × treatment: F(2, 32) = 24.04;
P < 0.00001), Cry2 mRNA (time × treatment: F(2, 32) = 4.41;
P = 0.022), REV-ERBα mRNA (treatment: F(2, 32) = 11.94;
P < 0.00001) and DBP mRNA (time × treatment: F(2, 32) = 5.93;
P = 0.007) mRNA. Furthermore, a decrease in Per2, Cry1, Cry2 and
DBP mRNA expression was found in MP-W rats. The effect of MPRED
treatment on the expression of clock genes in the adrenal also led to
changes in their AM/PM pattern. AM/PM variation was lost in BMAL
Per1, Per2, Cry1, Cry2, REV-ERBα and DBP mRNA of MP-T rats, and in
Cry1, Cry2 and DBP mRNA of MP-W rats. It is noteworthy that MPRED
treatment affected clock gene expression in the liver differently (Suppl.
Fig. 5) with no effects of treatment on Cry1, Cry2, REV-ERBbα and DBP.
Detailed results of statistical analysis are reported in Suppl. Table 3.
3.5. MPRED reduces glucocorticoid response to inflammation
One of the characteristics of SGCs-induced adrenal insufficiency is
the inability of the adrenal gland to mount an appropriate response to
stress and inflammation. In our previous experiment we showed that
the corticosterone response to ACTH is reduced in both MP-T and MP-W
rats (Fig. 1C). To estimate the functional relevance of decreased adrenal
activity following MPRED treatment we next tested whether MP-T and
MP-W rats also have a reduced adrenal response to acute inflammatory
stress. Following MPRED treatment rats were injected with LPS as
shown in Fig. 5A. We found that LPS-induced ACTH increase was re-
duced in MP-T rats, whereas ACTH levels were not different between
Ctrl and MP-W rats (LPS × treatment: F(2, 34) = 31.42; P < 0.00001).
However, both plasma corticosterone (LPS × treatment: F(2,
34) = 112.27; P < 0.00001) and adrenal corticosterone (LPS × treat-
ment: F(2, 34) = 47.26; P < 0.00001) levels were significantly reduced
in MP-T and in MP-W rats in response to LPS (Fig. 5B), suggesting that
the reduced corticosterone response to LPS depends on MPRED-induced
changes in the adrenal gland. Indeed, StAR mRNA expression in re-
sponse to LPS was also reduced in both MP-T and MP-W rats
(LPS × treatment: F(2, 34) = 4.70; P = 0.017; Fig. 5C). Detailed results
of statistical analysis are reported in Suppl. Table 3.
3.6. MPRED increases intra-adrenal pro-inflammatory cytokines expression
Because LPS can affect the adrenal gland both directly as well as by
inducing pro-inflammatory cytokines secretion from circulating im-
mune cells (Kanczkowski et al., 2015), we measured the expression of
intra-adrenal pro-inflammatory cytokines mRNA (Fig. 5B). We found
that MPRED was able to sensitize the adrenal to release pro-
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inflammatory cytokines in response to LPS, as shown by higher IL-1β
mRNA (LPS × treatment: F(2, 32) = 8.84; P = 0.001) and TNFα mRNA
(LPS × treatment: F(2, 34) = 67.67; P < 0.00001) mRNA levels in MP-T
rats, compared to Ctrl and MP-W rats (Fig. 5D and Suppl. Table 2). In
contrast, no significant increase in IL-6 mRNA was observed in MP-T
rats, while a significant increase was observed in both Ctrl and MP-W
rats (LPS: F(2, 34) = 212.09; P < 0.00001). This suggests that MPRED,
in parallel to reducing hormonal response to LPS - presumably by de-
creasing the systemic inflammatory response to LPS - can also exert pro-
inflammatory effects within the adrenal, as shown by an increased level
of intra-adrenal pro-inflammatory cytokines. To assess whether the
increased cytokine response in MP-T rats was associated with increased
microphages in the adrenal following LPS injection, we measured the
expression of the macrophage marker MHC II. We found that, while
MPRED treatment decreased MHC II mRNA expression in MP-T rats
(treatment: F(1, 34) = 8.52; P = 0.001), there was no effect of LPS in-
jection on MHC II mRNA across the experimental groups (Fig. 5D),
suggesting that the pro-inflammatory effect of MPRED is exerted at the
level of the adrenal and not within circulating macrophages. Pro-in-
flammatory effects of glucocorticoids have been previously shown in
other cell type and tissue, including immune cells, brain areas, pituitary
and liver (Frank et al., 2015). Therefore, we investigated whether the
pro-inflammatory effects of MPRED were specifically occurring in the
adrenal gland or similar effects could be seen in the liver. We found
that, in contrast with what was observed in the adrenal gland, MPRED
treatment reduced IL-1β mRNA and IL-6 mRNA response to LPS in the
liver (IL-1β: LPS × treatment: F(2, 30) = 4.67; P = 0.019; IL-6:
LPS × treatment: F(2, 30) = 5.45; P = 0.011), while no difference in
TNFα mRNA was observed between the three groups (Fig. 5E). Detailed
results of statistical analysis are reported in Suppl. Table 3.
3.7. MPRED increases intra-adrenal expression of pro-inflammatory factors
To investigate the mechanisms underlying the observed pro-in-
flammatory effects of MPRED in the adrenal – that is increased intra-
adrenal IL-1β and TNFα mRNA in response to LPS – we measured the
basal expression of genes encoding for modulators of the immune re-
sponse (Fig. 6). Overall, we found an effect of MPRED on TLR2 mRNA
(treatment: F(2, 32) = 3.43; P = 0.047), ANXA1 mRNA (time × treat-
ment: F(2, 32) = 6.20; P = 0.006), FPR2 mRNA (time × treatment: F(2,
32) = 3.84; P = 0.034), Casp1 mRNA (time × treatment: F(2, 32) = 3.86;
P = 0.034) and NFKB1α mRNA (time × treatment: F(2, 32) = 5.12;
P = 0.013), as well as on IL-6R mRNA (treatment: F(2, 32) = 8.83;
P = 0.001), and TNFαR mRNA (time × treatment: F(2, 32) = 4.98;
P = 0.014). Post-hoc test revealed a significant increase in ANXA1
mRNA in the AM in MP-T rats, and a significant decrease in FPR2
mRNA in the PM of both MP-T and MP-W rats. These data suggest that
the pro-inflammatory effects of MPRED in the adrenal may be mediated
by an increase in TLR expression, as well as an increase in the in-
flammatory mediator Annexin 1 (encoded by the Anxa1 gene). This
hypothesis is further supported by the observation that the anti-in-
flammatory effects of MPRED in the liver of MP-T rats were associated
with changes in TLR2 mRNA (treatment: F(2, 31) = 17.60;
P < 0.00001), TLR4 mRNA (treatment: F(2, 31) = 9.13; P = 0.001),
NLRP3 mRNA (treatment: F(2, 31) = 18.08; P < 0.00001), Casp1 mRNA
(treatment: F(2, 31) = 8.60; P = 0.001), and NFKB1α mRNA (treatment:
F(2, 31) = 10.26; P = 0.001), with a decreased expression of TLR2 and
NLPR3 mRNA in MP-T rats, and no effects on MP-W rats (Suppl. Fig. 5).
MPRED also induced changes in liver IL-1R mRNA (treatment: F(2,
31) = 8.30; P = 0.002), IL-6R mRNA (time × treatment: F(2, 32) = 4.53;
P = 0.021), and TNFαR (treatment: F(2, 31) = 3.45; P = 0.047) (Suppl.
Fig. 3. Effect of MPRED treatment and recovery on adrenal steroidogenic genes transcriptional regulators. The relative expression of mRNA of genes encoding for
transcription factors regulating the transcription of genes within the steroidogenic pathway was measured at 9 AM and at 5 PM in the adrenal gland of untreated rats
(control group, Ctrl), rats treated with methylprednisolone (MPRED) in the drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T), and rats treated with
MPRED for 5 days and then left to recover for 5 days (MPRED withdraw group, MP-W). Data are mean ± SEM of 5–8 rats/group and are expressed as fold induction
of AM-Ctrl. Data were analysed by two-way ANOVA and Tukey post-hoc test. *P < 0.05 vs Ctrl at the same time of day (effect of treatment); ^P < 0.05 vs MP-T at
the same time of day (effect of treatment); §P < 0.05 vs AM of the same treatment group (effect of time of day). Symbols in parentheses indicate a tendency to
significance (P < 0.10).
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Fig. 5). Detailed results of statistical analysis are reported in Suppl.
Table 3.
4. Discussion
In this study we have provided a detailed analysis of the effects of
the synthetic glucocorticoid MPRED on HPA axis activity and, im-
portantly, on genes that directedly or indirectly regulate steroid bio-
synthesis in the adrenal gland. Our data suggest a key role of proteins
regulating ACTH signalling (MRAP), cholesterol levels (HSL) and intra-
mitochondria availability (StAR and TSPO), as well as cholesterol en-
zymatic processing to corticosterone (CYP11a1, CYP21 and CYP11b1)
in the disruption of adrenal responsiveness observed in conditions of
MPRED-induced adrenal insufficiency. Furthermore, we provide evi-
dence for a decreased adrenal responsiveness to both ACTH and LPS
stimulation after 5 days MPRED treatment as well as after 5 days
withdrawal from MPRED. Importantly, we show that the down-
regulation of the adrenal gland observed after 5 days treatment are
associated with a pro-inflammatory effect of MPRED that appears to be
specific to the adrenal gland.
Clinical therapy with high doses of SGC results in adrenal in-
sufficiency, characterised by adrenal atrophy and decreased basal and
stress-induced cortisol secretion, that may persist for over 3 years after
SGC withdrawal (Joseph et al., 2016). Here we show that rats treated
with MPRED for 5 days show decreased adrenal weight and cortisol
secretion, both in basal and stress conditions, even 5 days after with-
drawing from the MPRED treatment. Interestingly, in addition to re-
duced hormone levels in recovering rats (MP-W group), pulsatile cor-
ticosterone pattern is also affected with decreased pulse length, inter-
pulse interval and pulse frequency. The effects of MPRED treatment on
pulse characteristics observed in the MP-W groups are not surprising.
Pulsatile corticosterone secretion depends both on dynamic responses
of the adrenal steroidogenic pathway to pulses of ACTH (Spiga et al.,
2017), as well as dynamic interactions between GC negative feedback
within the pituitary corticotroph cells and the hypothalamic secretion
of CRH (Walker et al., 2010, 2012). Therefore, it is plausible to spec-
ulate that long-term exposure to SGC may have affected GC signalling
in the anterior pituitary, and thus affected the feedforward-feedback
mechanisms regulating corticosterone pulsatility. Based on our math-
ematical modelling and in vivo work, changes in GC-regulated negative
feedback within pituitary corticotroph cells will impact the dynamics of
ACTH and, thus, GC secretion (Walker et al., 2010, 2012). Although AM
and PM ACTH levels were unaffected following MPRED withdraw, it is
possible that changes in the dynamics of ACTH (e.g. length and fre-
quency) may have occurred, resulting in the observed changes in cor-
ticosterone pulsatility. We have shown in a previous study that in-
travenous infusion of pulsatile ACTH in rats with MPRED-suppressed
HPA axis was able to recover steroidogenic function in the adrenal
(Spiga et al., 2011). Here we found that despite apparently normal
ACTH levels, steroidogenic function is still downregulated in MP-W
rats, further indicating that ACTH secretion in these rats is not com-
pletely restored (i.e. changes in ACTH dynamics), and a full recovery of
adrenal function (and ACTH dynamic) may only occur after a longer
withdrawal period.
In addition to this, we have recently shown that dynamics within
the adrenal steroidogenic pathway are crucial for normal ultradian
glucocorticoid secretion, and that disruption of these dynamics will
result in disrupted glucocorticoid synthesis (Spiga et al., 2017). Al-
though in this study adrenal steroidogenic gene expression was only
measured at two times of day it did reveal changes in their circadian
pattern of expression, supporting the speculation that that the observed
circadian changes are associated with ultradian changes which, in turn,
affect the dynamics of hormone synthesis and secretion. This is com-
patible with our model of the pulse generator, in which pulsatility
Fig. 4. Effect of MPRED treatment and recovery on adrenal clock genes. The relative expression of mRNA of clock genes was measured in the adrenal gland of
untreated rats (control group, Ctrl), rats treated with methylprednisolone (MPRED) in the drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T), and rats
treated with MPRED for 5 days and then left to recover for 5 days (MPRED withdraw group, MP-W) collected at 9 AM and at 5 PM. Data are mean ± SEM of 5–8
rats/group and are expressed as fold induction of AM-Ctrl. Data were analysed by two-way ANOVA and Tukey post-hoc test. *P < 0.05 vs Ctrl at the same time of
day (effect of treatment); ^P < 0.05 vs MP-T at the same time of day (effect of treatment); §P < 0.05 vs AM of the same treatment group (effect of time of day).
Symbols in parentheses indicate a tendency to significance (P < 0.10).
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within the pituitary-adrenal system not only depends on the feedback
inhibition, but also on the feedforward drive mediated by ACTH. Here
the delay in the adrenal response to ACTH play a crucial role in out
model, and such delay can be affected by changes within the ster-
oidogenic pathway that we have observed here in both MP-T and MP-W
rats. It is noteworthy that, while changes in GR and MR gene expression
were not observed in the pituitary, increased GR expression was found
in the hypothalamus of MP-W rats. The observed effect of MPRED on
hypothalamic GR could be due to decreased occupancy of GR since the
closely related prednisolone is a substrate of the multidrug resistance
(mdr) P-glycoprotein (Pgp) (Karssen et al., 2002). If MPRED, at least at
the doses used in this study, did not cross the blood brain barrier, it
would not be able to access the brain itself- as also suggested by a lack
of effect of MPRED on the GR-responsive genes SGK1 and GILZ in the
hypothalamus (data not shown).
Interestingly, adrenal corticosterone levels were also reduced in
both groups, suggesting that 1) reduced plasma corticosterone levels
are the result of reduced corticosterone synthesis in the adrenal gland,
and 2) although a reduction in circulating levels of ACTH may be re-
sponsible for reduced basal corticosterone secretion during the MPRED
treatment in MP-T rats, a direct effect of MPRED within the adrenal
steroidogenic pathway may be driving the long-term inhibition of
corticosterone secretion observed after MPRED withdraw in MP-W rats.
This is further supported by our findings that adrenal responsiveness to
exogenous ACTH is still reduced in MP-W rats. Tissue availability of
glucocorticoids depends on their binding to the transporter protein
Fig. 5. MPRED treatment reduces corticosterone response to LPS and increases adrenal cytokines mRNA levels. (A) Schematic representation of the LPS injection
experiments. (B) Plasma ACTH and corticosterone (P CORT), and adrenal corticosterone (A CORT), (C) adrenal StAR mRNA (D) adrenal and (E) liver pro-in-
flammatory cytokines IL-1β, IL-6 and TNFα mRNA were measured 2 h after LPS injection in untreated rats (control group, Ctrl), rats treated with methylprednisolone
(MPRED) in the drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T), and rats treated with MPRED for 5 days and then left to recover for 5 days
(MPRED withdraw group, MP-W). Data are mean ± SEM of 5–6 rats/group and are expressed as fold induction of Basal-Ctrl. Data were analysed by two-way
ANOVA and Tukey post-hoc test. +P < 0.05 vs LPS-untreated of the same MP treatment group (effect of LPS); *P < 0.05 vs Ctrl + LPS (effect of treatment);
^P < 0.05 vs MP + LPS (effect of treatment). Symbols in parentheses indicate a tendency to significance (P < 0.10).
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corticosteroid binding globulin (CBG). Consistent with previous evi-
dence (Smith and Hammond, 1992), liver CBG mRNA expression was
highly reduced in MP-T rats whereas it was unaffected in MP-W rats
(Suppl. Fig. 7), suggesting that the decreased levels of plasma corti-
costerone in this group will result in reduced hormone levels at tissue
level.
The increase in GCs secretion upon ACTH stimulation is rapid (< 5
min); however, because of their lipophilic nature, GCs cannot be pre-
stored in vesicles but must be de novo synthesized from its precursor,
cholesterol. This process requires ACTH-mediated non-genomic me-
chanisms involving the rapid activation of steroidogenic proteins, in-
cluding hormone-sensitive lipase (HSL) and steroidogenic acute reg-
ulatory (StAR) proteins, which regulate cellular availability and intra-
mitochondrial levels or cholesterol, respectively (Lin et al., 1995;
Kraemer and Shen, 2002). ACTH also activates mitochondrial ster-
oidogenic enzymes belonging to the cytochrome P450 (CYP) and hy-
droxysteroid dehydrogenase (HSD) families, which, in the rat, convert
cholesterol into corticosterone (Midzak and Papadopoulos, 2016). In
parallel, in order to maintain optimal steroidogenic response to further
stimuli, ACTH simultaneously triggers genomic responses involving the
transcription of genes encoding for the above-mentioned steroidogenic
proteins and enzymes. We have previously shown that 5-days treatment
with MP induces a reduction in the expression of steroidogenic genes in
the adrenal gland (Spiga et al., 2011). In the present study we con-
firmed and expanded upon our previous work by showing that pro-
longed treatment with MPRED lead to changes in the expression of
several genes encoding for steroidogenic proteins in the adrenal gland.
A recent study has revealed that some steroidogenic gene promoter,
including Cyp11a1, Cyp11b1 and HSDb2, contains a negative GRE
(Wang et al., 2019), and this suggests that their expression is directly
regulated by MPRED (and the endogenous corticosterone). Other ster-
oidogenic genes, including StAR and MC2R, are downregulated by GCs
via increased expression of the negative regulator DAX-1 (Gummow
et al., 2006). Notably, the effects of MPRED on StAR, TSPO and HSL
mRNA appear to be specific to the adrenal gland, as opposite effects on
these genes were observed in the liver (Suppl. Fig. 8).
The effects of MPRED on adrenal steroidogenic gene expression was
paralleled by changes in the expression of their transcriptional reg-
ulators and in the expression of several key clock genes, suggesting that
both direct and indirect effects of MPRED may be responsible for the
changes in steroidogenic activity in the adrenal gland. It was note-
worthy that MPRED treatment resulted in decreased adrenal expression
of the clock gene Per1, and other genes known to be induced by glu-
cocorticoids via activation of GR including GILZ and FKBP5 (Suppl.
Fig. 9A), whereas these genes were all induced in the liver. The me-
chanisms underlying the differential effect of GR activation between the
adrenal and the liver is not clear, and further studies on the MPRED-
induced binding of GR to Per1 promoter in the adrenal would be
needed to elucidate this.
While from our data it is clear that suppressed steroidogenic func-
tion after 5-days MPRED treatment may be a direct effect of the SGC
treatment, the mechanisms underlying the effects observed after 5 days
withdrawal are less clear. It is unlikely that circulating MPRED is still
present and/or is still exerting direct effects due to relative short half-
life of the hormone (approx. 2.5 h in male rats) (Ayyar et al., 2019b), as
also suggested by rapid body weight gain upon removal of the treat-
ment (Suppl. Fig. 1) and lack of effect on GC-responsive genes GR,
FKBP5 and GILZ mRNA both in the adrenal and in the liver of MP-W
rats (Suppl. Fig. 9A and B). The mechanisms through which MRED af-
fect the steroidogenic pathway in the withdrawal period are not clear
from our data, and further studies are needed to focus on GR activity
and function within the adrenal gland.
One of the pathological consequences of SGC-induced adrenal in-
sufficiency is the potential development of an adrenal crisis resulting
from decreased endogenous GC secretion in response to inflammatory
stressors such as infections, injuries and major surgery. Consistent with
clinical data, administration of LPS in MP-T rats resulted in suppressed
ACTH and corticosterone responses, due to the suppressive effect of
MPRED. However, despite a normal ACTH response, both plasma and
adrenal corticosterone response was reduced in MP-W rats, suggesting
Fig. 6. Effect of MPRED treatment and recovery on adrenal inflammatory factors. The relative expression of genes encoding for key inflammatory markers and
modulators was measured at 9 AM and at 5 PM in the adrenal gland of untreated rats (control group, Ctrl), rats treated with methylprednisolone (MPRED) in the
drinking water (1 g/L) for 5 days (MPRED treatment group, MP-T), and rats treated with MPRED for 5 days and then left to recover for 5 days (MPRED withdraw
group, MP-W). Data are mean ± SEM of 5–8 rats/group and are expressed as fold induction of AM-Ctrl. Data were analysed by two-way ANOVA and Tukey post-hoc
test. *P < 0.05 vs Ctrl at the same time of day (effect of treatment); §P < 0.05 vs AM of the same treatment group (effect of time of day). Symbols in parentheses
indicate a tendency to significance (P < 0.10).
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that, as observed in human patients, the effect of prolonged SGC
treatment can still affect adrenal activity even after discontinuation of
the treatment. It was interesting to observe that the adrenal expression
of the pro-inflammatory cytokines IL-1β and TNFα in response to LPS
was elevated in MP-T rats compared to Ctrl, while IL-6 expression was
decreased. We were surprised to observe a discrepancy between the
effects on IL-1β and TNFα, and on IL-6, and further studies on the
mechanisms behind these differences are needed. However, Frank and
colleagues have shown a similar result with corticosterone treatment
increasing IL-1β and TNFα mRNA in hippocampal microglia in response
to LPS, with no effect on IL-6 mRNA (Frank et al., 2010). Indeed, a pro-
inflammatory effect of GC has been previously reported in immune
cells, in the hippocampus and in the liver (Frank et al., 2010; Busillo
et al., 2011; Frank et al., 2013). It is noteworthy that, despite a decrease
in corticosterone response, the expression of adrenal cytokines in re-
sponse to LPS was not affected in MP-W rats. Indeed, an increase in
cytokine expression was expected, due to the well characterised re-
duced corticosterone-mediated anti-inflammatory effect. Nevertheless,
a pro-inflammatory effect of MPRED in the adrenal during the treat-
ment can have functional consequences. Pro-inflammatory cytokines,
including IL-1β, IL-6 and TNFα, play a key role in the immune-adre-
nocortical cross-talk as they can directly modulate adrenal function
(Kanczkowski et al., 2015). Indeed, IL-1β, IL-6 and TNFα can stimulate
adrenal steroidogenesis in vivo in the rat (Spiga et al., 2017). Given that
MPRED treatment decreased LPS-induced corticosterone secretion in
both MP-T and MP-W rats, it is plausible to speculate that any effect of
cytokines on corticosterone secretion would have been masked by the
effects of MPRED. Furthermore, intra-adrenal activation of the immune
system can also affect adrenal functionality by damaging adrenal en-
dothelial microvascular cells (Chen et al., 2019). In addition to this,
both synthetic glucocorticoids and pro-inflammatory cytokines can
decrease adrenal steroidogenic function by inducing apoptosis and re-
ducing cell viability (Mikhaylova et al., 2007; Finco et al., 2018).
The mechanisms underlying the pro-inflammatory effects of GCs are
still matter of investigation and several mechanisms have been pro-
posed, including (1) an increase expression of TLR and/or cytokines
receptors, (2) an increase in macrophagic levels and/or activity, and (3)
an increase in the expression of the NLP3 inflammasome component
NLP3 and Casp1 (Busillo et al., 2011; Frank et al., 2014). Consistent
with this evidence, we found that MPRED-induced pro-inflammatory
response to LPS was associated with increased basal levels of both TLR2
and TLR4 expression in MP-T rats. TLR4 is the primary receptor for
Gram-negative bacterial LPS, while TLR2 functions as the primary re-
ceptor for recognition of Gram-positive bacterial cell wall components.
There is evidence that the cellular responses to LPS requires both TLR4
and TLR2 (Good et al., 2012), therefore, based on our findings, it is
plausible to speculate that the increase in TLR2 mRNA expression may
lead to increased activity of TLR4, thus increased adrenal responsive-
ness to LPS. Interestingly, MPRED induced the expected anti-in-
flammatory effects in the liver and this was associated with a significant
decrease in both TLR2 and TLR4 mRNA expression. In addition, we
found an increase ANXA1 mRNA, a GC-induced gene encoding for the
inflammatory mediator Anexin1, in the adrenal. Previous studies have
shown that a decrease in ANXA1 expression is linked to an increase in
TLR4-mediated responses, a decrease in pro-inflammatory cytokines
response to LPS and increased anti-inflammatory effects of GCs (Davies
et al., 2007). Thus, this is consistent with the observed decrease in
corticosterone response to LPS, and with increased expression of pro-
inflammatory cytokines in MP-T rats. Notably, the expression of ANXA1
receptor FPR2 was decreased both in MP-T and MP-W rats, suggesting
compensatory mechanisms within the Anexin1 pathways.
Glucocorticoids induce the formation of the inflammasome, a mul-
tiprotein signalling-complex that includes the GC-responsive gene nod-
like receptor 3 (NLRP3) (Leemans et al., 2011). Assembly and activa-
tion of the NLRP3 inflammasome leads to activation of caspase 1 (en-
coded by the casp1 gene) which induces the cleavage of pro-IL-1β to its
mature form IL-1β (Martinon et al., 2009). In the present study, we
found no significant changes on the expression of either NLRP3 or
CASP1 in the adrenal therefore it is unclear from our data whether the
pro-inflammatory effects of SGC in the adrenal gland involve the in-
flammasome complex. LPS binding to TLR4 activates the NF-kB
pathway and, in turn, SGCs repress inflammation by inducing the ex-
pression of the NF-kB repressor NFKB1α (Munhoz et al., 2010). Para-
doxically, NFKB1α is also induced by NF-kB, thus an increase in
NFKB1α can be used as a marker of pro-inflammatory effect of NF-kB
(Sun et al., 1993). We show here a significant overall effect of MPRED
on NFKB1α that was associated with a pattern of increase in MP-T rats,
thus suggesting its involvement in the pro-inflammatory effect of SGC.
Unfortunately, experimental constraints precluded an assessment of
the temporal changes in hormone secretion and gene expression fol-
lowing LPS injections (experiment 3), and of gene expression following
ACTH administration (experiment 1). Our recent work has shown that
the adrenal steroidogenic pathway responds dynamically to both ACTH
and LPS perturbations (Spiga et al., 2017) and therefore it would be
important to asses MPRED effects on steroidogenic activity not only in
term of absolute changes but also in term of pattern of response. One
other limitation of our data is that we only performed this study using
male rats. Sexual dimorphism in basal HPA axis activity, as well as in its
response to stress and in systemic response to inflammation has been
well characterised. Furthermore, glucocorticoid receptor signalling has
also been shown to be different between male and female rats (Goel
et al., 2014). In addition, MPRED metabolism has been shown to be
different in male and female rats (Ayyar et al., 2019a), therefore, we
cannot exclude that MPRED may affect adrenal corticosterone dy-
namics and adrenal steroidogenesis differently in male and female rats.
Therefore, based on the present data, future studies should be designed
to take into consideration sex differences in adrenal activity and their
underlying molecular mechanisms in the context of models of adrenal
insufficiency.
In summary, in this study we have provided a thorough analysis of
the effects of the synthetic glucocorticoid methylprednisolone on HPA
axis activity and, importantly, on genes that directly or indirectly reg-
ulate steroid biosynthesis in the adrenal gland. Our data provide va-
luable insights on the regulation of the adrenal steroidogenic pathway
that are important starting points for future studies on adrenal gland
physiology. Importantly, the results of this study further expand our
knowledge of the mechanisms through which synthetic glucocorticoids
induce adrenal insufficiency, by showing simultaneous effects within
multiple pathways involved in steroidogenesis, including circadian
clock gene and inflammation pathways. Furthermore, we show here for
the first time a pro-inflammatory effect of synthetic glucocorticoids in
the adrenal gland. A more detailed understanding of the effects of
synthetic glucocorticoids on HPA axis dynamics and on adrenal ster-
oidogenic activity in basal conditions and in response to immune stress,
and the identification of mechanisms regulating these effects, will help
the development of more rational therapeutic strategies.
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